Company News

FACTBOX-Global pharma to pump cash into Russia

MOSCOW, Nov 26 (Reuters) - Global drugmakers are set to pour more than $1 billion into Russian manufacturing in a bid to sidestep a tougher government stance on imported medicines. [ID:nLDE6570W4]

Following are international pharmaceuticals producers which have existing facilities in Russia, have announced plans to set up local manufacturing sites, or are considering such a move:

GLAXOSMITHKLINE GSK.L -- The British group and Moscow-based Binnopharm, a unit of Sistema SSAq.L, have agreed to let the Russian firm make Glaxo's cervical cancer, rotavirus and pneumococcal vaccines for the Russian market. [ID:nLDE6AP0TE]

Glaxo already has a hepatitis vaccine filling and packaging plant as part of a joint venture with local Russian partners.

TEVA TEVA.O -- Israel's Teva plans to invest up to $100 million in a drug production plant in Russia as it aims to more than triple Russian sales by 2015, a Russian executive told Reuters in July. [ID:nLDE66S151]

NOVO NORDISK NOVOb.CO -- The world's No.1 insulin maker said in April it would invest $80 million-$100 million to build its first production facility in Russia. [ID:nLDE63S15P]

SANOFI-AVENTIS SASY.PA -- A Russian government commission approved in May the company's acquisition of a controlling stake in a Russian insulin plant after the firm said in November it would take part in the government's Pharmpolis Project, aimed at making global firms produce medicines in Russia. [ID:nWEA3374]

NYCOMED [NYCMD.UL] -- The privately owned Swiss drugmaker said in September it would invest 65-75 million euros ($86-$99 million) by 2014 to build a liquid sterile products and solid medicines production plant in Russia. [ID:nLM543423]

JOHNSON & JOHNSON JNJ.N -- Struck agreement with Russian company Pharmstandard PHST.MM to localise secondary packaging of its cancer drug Velcade in Pharmstandard's production plant.

ASTRAZENECA AZN.L -- The Anglo-Swedish drugmaker said in March it was considering locating manufacturing of key products in Russia. [ID:nLDE62I1L4]

NOVARTIS NOVN.VX -- The Swiss drugmaker said in November it wanted to make acquisitions in emerging markets, including Russia. [ID:nLDE6AG164]

PFIZER PFE.N -- The head of Pfizer's emerging markets unit said in January the drugmaker planned a big push into high-growth underdeveloped countries, with an initial focus on Russia along with China, Mexico, Turkey, Brazil and India. [ID:nN19224267]

KRKA KRKG.LJ -- The Slovenian drug firm said in January it planned to triple production capacity at its factory near Moscow, built in 2003, over the next three years in what will be one of its major investments in 2010. [ID:nLDE60L19W]

GEDEON RICHTER GDRB.BU -- The Hungarian drugmaker, which has a manufacturing and packaging plant near Moscow, in April raised its stake in Russian drug firm Protek PRTK.MM to 5 percent from 4 percent. [ID:nLDE63S1LZ]

SERVIER -- The French company built a tablet production factory in the Moscow region in 2007.

STADA STAGn.DE -- The German drugmaker became Russia's second-largest local producer after buying Nizhpharm in 2005 and Makiz-Pharma in 2007.

FRESENIUS MEDICAL CARE FMEG.DE -- The world's largest kidney dialysis company, a unit of German healthcare conglomerate Fresenius FREG_p.DE, said in July it agreed to acquire a private operator of dialysis clinics in Russia's southern Krasnodar region. [ID:nWEA7899]

Reporting by Maria Kiselyova; Editing by Michael Shields